HK Stock Market Move | LEPU BIO-B(02157) rose nearly 6% as EGFR ADC drug Vebracotuximab was applied for listing.

LEPU BIO-B (02157) rose by nearly 6%, as of the time of publication, it rose by 5.76%, to 3.12 Hong Kong dollars, with a turnover of 5.6179 million Hong Kong dollars. On the news side, on September 25, the CDE official website showed that Lepu Bio's EGFR ADC Vebicotad monoclonal antibody (MRG003) has applied for listing, for the treatment of recurrent/metastatic nasopharyngeal cancer patients who have previously failed at least second-line systemic chemotherapy and PD-1/PD-L1 inhibitors. Insight database shows that there are currently no EGFR-targeting ADCs approved for listing in China. Lepu's MRG003 is the first domestically applied for listing EGFR ADC. Lepu Bio's semi-annual report for 2024 shows that MRG003 for nasopharyngeal cancer indications has been granted breakthrough therapy designation by the US FDA and has been included in breakthrough treatment varieties by the CDE. Currently, Lepu Bio has completed patient enrollment in the phase 2b registration clinical study of MRG003 for nasopharyngeal cancer. In addition, the product is also actively enrolling patients in the phase 3 clinical registration study for head and neck squamous cell carcinoma.